COMPASS Pathways

10 clinical trials to watch in the first half of 2025
BioPharma Dive
Thu, 01/2/25 - 11:42 am
clinical trials
Eli Lilly
cardiovascular disease
Arvinas
protein degradation
Vera Therapeutics
IgA nephropathy
Novarts
pelacarsen
Entyvio
IBD
Novo Nordisk
Alzheimer's disease
Beam Therapeutics
sickle cell disease
COMPASS Pathways
psychedelics
Moderna Therapeutics
Verve Therapeutics
high cholesterol
Compass veers off course, delaying phase 3 psychedelic data and laying off 30% of staff
Fierce Biotech
Thu, 10/31/24 - 09:18 am
COMPASS Pathways
clinical trials
psychedelic drugs
depression
After an FDA rejection, here’s what’s next in the psychedelics pipeline
BioPharma Dive
Wed, 08/28/24 - 11:41 am
psychedelics
FDA
Lykos Therapeutics
COMPASS Pathways
Incannex Healthcare
MindMed
Largest psilocybin trial finds the psychedelic is effective in treating serious depression
Stat
Tue, 11/9/21 - 11:37 pm
psychedelic drugs
psilocybin
treatment-resistant depression
COMPASS Pathways
clinical trials
MindMed aims for Nasdaq listing after Compass’ magic mushroom-fuelled IPO
Pharmaforum
Tue, 09/22/20 - 12:13 pm
COMPASS Pathways
IPOs
Mind Medicine
psychedelic drugs
magic mushrooms
Compass raises $80M to take magic mushroom drug toward phase 3
Fierce Biotech
Mon, 04/27/20 - 09:25 am
COMPASS Pathways
psilocybin
magic mushrooms
treatment-resistant depression
In a key step for psychedelic research, magic mushroom compound clears first clinical safety hurdle
Endpoints
Thu, 12/12/19 - 05:35 pm
antidepressants
COMPASS Pathways
psilocybin
Psilocybin Therapy for Treatment-Resistant Depression is Being Taken Seriously by Regulators as FDA Gives Go-Ahead to Clinical Trial
Xtalks
Fri, 08/24/18 - 11:03 am
COMPASS Pathways
FDA
psilocybin
treatment-resistant depression